Martin Schlumberger

Martin Schlumberger is one of Europe's foremost authorities on differentiated thyroid cancer and radioiodine therapy at Gustave Roussy. He co-led the SELECT trial with lenvatinib and the DECISION trial with sorafenib, defining modern systemic therapy for RAI-refractory thyroid cancer. His career spans over three decades of contributions to thyroid cancer diagnosis, treatment, and molecular characterization. He has been central to the European Thyroid Association's clinical practice guidelines.